Robert Lakin

Robert Lakin

InvestorPlace Contributor

A journalist — both writer and editor — Robert has covered markets and economies for more than 20 years. His previous gigs include Bloomberg News, where he was emerging markets editor in Tel Aviv, McKinsey & Co. and McDonald & Company Investments, where he was equities research editor.

His deep experience includes covering startups, emerging markets, financial services, and capital markets.

He writes a Substack newsletter, TLV Strategist, which covers the Israel business scene.

Recent Articles

TLRY Stock: The News That Has Cannabis Giant Tilray Moving Today

By Robert Lakin, InvestorPlace Contributor

While lockdowns in Ontario hit Tilray's revenue during Q4, the Canadian pot producer saw sales increase 27%. Its now-complete Aphria merger is beginning to show positive effects.

EYEG Stock: 2 Big Things to Know About EyeGate Pharma as Shares Soar 100%+

By Robert Lakin, InvestorPlace Contributor

EYEG stock continues its acquisition plans with its intent to buy Bayon Therapeutics in an all-stock transaction. Here's what to know.

Big Tech Earnings Today: What to Expect From AAPL, GOOGL and MSFT

By Robert Lakin, InvestorPlace Contributor

All eyes are on Big Tech earnings today ahead of reports from three of the biggest players: Apple, Alphabet and Microsoft.

Bitcoin Mining Stocks: What’s Going on With RIOT, MARA, SOS, HVBT and BTBT Today?

By Robert Lakin, InvestorPlace Contributor

Bitcoin mining stocks are riding a move by BTC-USD past $39,000 for the first time in six weeks, with RIOT and HVBT leading the pack.

Amazon Bitcoin News: The Rumored Crypto Plans Sending BTC Prices to a 6-Week High

By Robert Lakin, InvestorPlace Contributor

This morning's Amazon Bitcoin news is taking the internet by storm. A job listing has sparked rumors that Amazon will soon accept crypto.

Couchbase IPO: Here’s What Potential BASE Stock Investors Should Know

By Robert Lakin, InvestorPlace Contributor

With BASE stock, the Couchbase IPO signals what's expected to be a strong second half of the year for new listings. Here's what to know.

EYES Stock: The Artificial Vision News That Has Investors Looking at Second Sight

By Robert Lakin, InvestorPlace Contributor

EYES stock is set for another day of double-digit gains after the European patent agency approved the company's application.

KO Stock: 5 Reasons Why Coke Investors Have a Smile Today

By Robert Lakin, InvestorPlace Contributor

KO stock is popping on the company's Q2 results, which boasted strong numbers and caused the company to raise its full year guidance.

CEMI Stock: $28M Covid Test Order Sends Chembio Diagnostics Skyrocketing

By Robert Lakin, InvestorPlace Contributor

CEMI stock is soaring after inking its first multi-million dollar sales contract for its FDA-approved Covid-19 rapid antigen test.

ARDX Stock: Disastrous FDA News Sends Ardelyx Shares Plummeting

By Robert Lakin, InvestorPlace Contributor

News from the FDA is not good for ARDX stock. Investor reaction has been swift and harsh, as is often the case with risky biotech stocks.

Load More